Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05591222 · ClinicalTrials.gov registry record · Phase 2
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
A Phase 2 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT05591222 is a Phase 2 study that was terminated before completion, run by Amgen. The registered enrollment target is 72 participants.
The verdict
NCT05591222, a Phase 2 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
Interventions
- DRUG Placebo
- DRUG Daxdilimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2025-05-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05591222
The ClinicalTrials.gov registry entry for NCT05591222 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05591222 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05591222 about?
NCT05591222 is a clinical study titled "Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus". A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to standard of care.
What is the current status of trial NCT05591222?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2022-12-29. Estimated completion is 2025-05-08.
What interventions are being tested in trial NCT05591222?
The interventions under investigation include: Placebo (DRUG), Daxdilimab (DRUG).
Who is sponsoring clinical trial NCT05591222?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.